Insulin therapy for type 1 diabetes comes with specific challenges such as the requirement for injections, which can be uncomfortable and inconvenient. Patients must also constantly monitor their blood glucose levels to adjust insulin doses, which demands careful management to avoid hypoglycemia. In contrast, oral agents for type 2 diabetes allow for easier administration and include options conducive to managing insulin resistance and enhancing secretion versus the singular challenge of direct insulin deficiency in type 1 diabetes .

GLP receptor agonists, such as liraglutide and exenatide, are typically administered orally and work by mimicking incretin hormones to stimulate insulin release, thereby reducing blood glucose levels post-meal. In contrast, insulin therapy for diabetes mellitus, especially type 1, involves direct insulin injection since these patients do not produce insulin naturally. Insulin therapy is crucial in type 1 diabetes where insulin is absent, while GLP receptor agonists are more common in type 2 diabetes, where insulin resistance rather than absence is the issue .

Oral hypoglycemic agents are significant in the management of type 2 diabetes mellitus due to their convenience of administration and their ability to target the multiple pathophysiological disturbances inherent in type 2 diabetes. They help increase insulin secretion, reduce glucose absorption, and address insulin resistance, providing a broad approach essential in a condition characterized by complex metabolic dysfunctions. Their role is crucial for long-term glycemic control and minimization of complications, underscoring their importance in comprehensive diabetes care .

Antidiabetic drugs are classified into several categories based on their mechanisms of action. Some classes include sulfonylureas, which increase insulin secretion from the pancreas; biguanides, which decrease hepatic glucose production and increase insulin sensitivity of peripheral tissues; and thiazolidinediones, which improve insulin action by enhancing insulin sensitivity. Additionally, GLP-1 receptor agonists like liraglutide and exenatide mimic incretin hormones to increase insulin release in response to meals. These drugs can be broadly divided into those that enhance insulin secretion, improve insulin sensitivity, slow glucose absorption in the intestines, or increase glucose excretion through the kidneys .

Traditional medicine practices contribute substantially to the global management of diabetes by providing accessible and cost-effective treatment options, particularly in regions with limited access to conventional medical care. Botanical medicines play a pivotal role by offering diverse biological compounds capable of lowering blood glucose levels. These natural therapies can complement conventional treatments, potentially improving therapeutic outcomes and providing a more holistic approach to diabetes management. The usage of plant-based medicines like Allium sativum and Gymnema sylvestre represents this integration and highlights the potential of diverse phytochemical constituents to modulate diabetic parameters .

Herbal anti-diabetic medicines play a supportive role in diabetes management, often used as complementary therapies alongside conventional treatments. They are derived from botanicals and medicinal plants, with traditional usage by approximately 60% of the global population. Notable examples of herbal medicines with antidiabetic effects include Allium sativum (garlic), Eugenia jambolana (Java plum), Momordica charantia (bitter melon), Ocimum sanctum (holy basil), and Gymnema sylvestre, among others .

The treatment of type 1 diabetes mellitus primarily involves insulin administration because it is characterized by a lack of insulin production, necessitating direct insulin injections to manage blood glucose levels. In contrast, type 2 diabetes mellitus, which involves insulin resistance, employs a range of treatments aimed at increasing insulin secretion, enhancing insulin sensitivity, slowing glucose absorption from the gut, and augmenting glucose loss through urination. These differences are critical as they address the underlying pathophysiological mechanisms specific to each type of diabetes, ensuring effective management of blood glucose levels and prevention of complications .

Glimepiride is a sulfonylurea, a class of antidiabetic drugs that primarily functions by stimulating the beta cells in the pancreas to increase insulin secretion. This mechanism is especially useful in type 2 diabetes mellitus where there is insulin resistance and an inadequate insulin response. By targeting the pancreatic beta cells, Glimepiride increases the availability of insulin to overcome resistance in bodily tissues, thereby lowering blood glucose levels .

Diabetes mellitus type 1 is marked by the autoimmune destruction of pancreatic beta cells, leading to an absolute deficiency in insulin production. Consequently, patients with type 1 diabetes require external insulin to regulate blood glucose levels. In contrast, type 2 diabetes involves insulin resistance where cells fail to respond adequately to insulin despite sufficient production initially. Over time, insulin secretion may decrease as beta cells become dysfunctional, necessitating treatments that improve insulin sensitivity or promote its release .

The choice of an antidiabetic drug for a patient with type 2 diabetes mellitus is influenced by several factors, including the severity of the disease, patient age, existing comorbidities, lifestyle, and preferences. Additionally, considerations about the mechanism of action—whether the drug increases insulin secretion, improves tissue sensitivity to insulin, or reduces glucose absorption—play a key role. The patient's kidney function and risk of hypoglycemia are also critical in determining the appropriate treatment regimen .